Dongsung Pharmaceutical동성제약
002210 · KOSPI · ₩002210 · 동성제약
₩1,196▼ ₩27 (2.21%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩87B | ₩88B | ₩89B | ₩93B | ₩84B |
| Cost of sales | ₩50B | ₩50B | ₩47B | ₩51B | ₩51B |
| Gross profit | ₩37B | ₩39B | ₩41B | ₩42B | ₩34B |
| Operating income | −₩10B | −₩5.7B | ₩596M | −₩3.1B | −₩5.3B |
| Net income | −₩26B | −₩15B | −₩2.1B | −₩2.1B | −₩4.3B |
| Net income to shareholders | −₩26B | −₩15B | −₩2.1B | −₩2.1B | −₩4.3B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩168B | ₩141B | ₩115B | ₩108B | ₩105B |
| Current assets | ₩89B | ₩57B | ₩61B | ₩54B | ₩50B |
| Cash and equivalents | ₩3.9B | ₩3.1B | ₩6.4B | ₩4.1B | ₩3.1B |
| Total liabilities | ₩145B | ₩97B | ₩75B | ₩65B | ₩58B |
| Current liabilities | ₩130B | ₩77B | ₩45B | ₩48B | ₩38B |
| Borrowings | ₩64B | ₩52B | ₩43B | ₩45B | ₩29B |
| Total equity | ₩23B | ₩44B | ₩40B | ₩43B | ₩46B |
| Shareholders' equity | ₩23B | ₩44B | ₩40B | ₩43B | ₩46B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩13B | −₩6.7B | −₩4.3B | −₩3.9B | −₩2.8B |
| Free cash flow | −₩13B | −₩6.7B | −₩4.3B | −₩3.9B | −₩2.8B |
Consolidated where available. Amounts in won.
Also known as: Dongsung Pharmaceutical / 동성제약 / 002210 / KRX:002210
Source: KRX statistical information